Frank Pauline, Laurent Julie, Dallas Lorraine, Varriale Pasquale, Ciupek Andrew
Novartis Pharma AG, Basel, Switzerland.
, 8634, Hombrechtikon, Switzerland.
Oncol Ther. 2025 Mar;13(1):145-164. doi: 10.1007/s40487-024-00314-2. Epub 2024 Dec 19.
This research sought to identify trends in the patient with lung cancer (LC) care pathway, experiences, and needs, across geographies and healthcare settings.
Patients living with LC for more than 18 years in nine countries completed an online survey covering these domains-demographic, disease, treatment, and patient preferences for information and support services. Recruitment was primarily from patient with LC communities on online platforms.
A total of 1000 patients with LC completed the survey across Europe (49%), North America (29%), and Asia (22%). Demographics of participants were different to what has been reported in literature-there were a lower proportion of type non-small cell lung cancer (NSCLC), a higher proportion of type small cell lung cancer (SCLC), a higher rate of early-stage diagnosis, and a younger population. There were 56% male participants. Although physicians were the main stakeholders influencing treatment choice and quality of life (QoL) discussions, the patient's family/relatives ranked highly as important stakeholders. The top reasons patients reported choosing a treatment were related to efficacy, and hesitation to start a treatment was related to concerns about side effects. QoL was an important factor in both cases. Patients are impacted physically, socially, and mentally-50% report an impact on employment status, 48% report daily difficulties in mental well-being, and 64% have received psychological support or would like to. Disparities were observed across countries in genetic/biomarker testing completed or planned (30-88%) and being asked to participate in clinical trials (15-49%), which reflects the status of how different patient with LC care pathways have adopted innovation in LC care.
Both medical and external factors impact experiences and outcomes of patients living with LC, including the role of family in treatment and QoL discussions. There are intercountry differences in knowledge and disease management.
本研究旨在确定肺癌（LC）患者护理途径、经历和需求在不同地域和医疗环境中的趋势。
九个国家中患有LC超过18年的患者完成了一项涵盖这些领域的在线调查，包括人口统计学、疾病、治疗以及患者对信息和支持服务的偏好。招募主要来自在线平台上的LC患者群体。
共有1000名LC患者完成了调查，其中欧洲占49%，北美占29%，亚洲占22%。参与者的人口统计学特征与文献报道不同——非小细胞肺癌（NSCLC）类型的比例较低，小细胞肺癌（SCLC）类型的比例较高，早期诊断率较高，且人群更年轻。男性参与者占56%。尽管医生是影响治疗选择和生活质量（QoL）讨论的主要利益相关者，但患者的家人/亲属作为重要利益相关者的排名也很高。患者报告选择治疗的首要原因与疗效相关，而对开始治疗的犹豫与对副作用的担忧有关。在这两种情况下，QoL都是一个重要因素。患者在身体、社会和心理方面都受到影响——50%的人报告就业状况受到影响，48%的人报告日常心理健康存在困难，64%的人已经接受过心理支持或希望获得心理支持。各国在已完成或计划进行的基因/生物标志物检测（30 - 88%）以及被要求参与临床试验（15 - 49%）方面存在差异，这反映了不同LC患者护理途径在LC护理中采用创新的情况。
医学因素和外部因素都会影响LC患者的经历和结果，包括家庭在治疗和QoL讨论中的作用。各国在知识和疾病管理方面存在差异。
